相似文献
1
Editorial: Resistance to Medical Therapy in Pituitary Tumors.
Front Endocrinol (Lausanne). 2022 Feb 23;13:861230. doi: 10.3389/fendo.2022.861230. eCollection 2022.
2
Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
Mol Cell Endocrinol. 2008 May 14;286(1-2):206-13. doi: 10.1016/j.mce.2007.12.008. Epub 2007 Dec 23.
3
The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology.
J Mol Endocrinol. 2009 May;42(5):361-70. doi: 10.1677/JME-08-0162. Epub 2009 Jan 13.
4
Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.
J Mol Endocrinol. 2005 Oct;35(2):333-41. doi: 10.1677/jme.1.01876.
5
Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
Neuroendocrinology. 2006;83(3-4):258-63. doi: 10.1159/000095536. Epub 2006 Oct 13.
6
Diagnosis and treatment of pituitary adenomas.
Minerva Endocrinol. 2004 Dec;29(4):241-75.
7
Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours.
Eur J Endocrinol. 2007 Apr;156 Suppl 1:S57-S63. doi: 10.1530/eje.1.02348.
8
Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas.
Endocr J. 2009;56(4):579-84. doi: 10.1507/endocrj.k08e-186. Epub 2009 Mar 24.
9
[New medical treatments in pituitary adenomas].
Ann Endocrinol (Paris). 2008 Sep;69 Suppl 1:S16-28. doi: 10.1016/S0003-4266(08)73964-7.
10
[Treatment of pituitary adenomas].
Orv Hetil. 2009 Sep 27;150(39):1803-10. doi: 10.1556/OH.2009.28584.
引用本文的文献
1
Somatostatin Receptor Gene Functions in Growth Regulation in Bivalve Scallop and Clam.
Int J Mol Sci. 2024 Apr 28;25(9):4813. doi: 10.3390/ijms25094813.
本文引用的文献
1
A Pituitary Society update to acromegaly management guidelines.
Pituitary. 2021 Feb;24(1):1-13. doi: 10.1007/s11102-020-01091-7. Epub 2020 Oct 20.
2
Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor.
J Clin Endocrinol Metab. 2020 Dec 1;105(12):3807-20. doi: 10.1210/clinem/dgaa649.
3
Aggressive and Malignant Prolactinomas.
Neuroendocrinology. 2019;109(1):57-69. doi: 10.1159/000497205. Epub 2019 Jan 24.
4
cAMP/PKA-induced filamin A (FLNA) phosphorylation inhibits SST2 signal transduction in GH-secreting pituitary tumor cells.
Cancer Lett. 2018 Oct 28;435:101-109. doi: 10.1016/j.canlet.2018.08.002. Epub 2018 Aug 8.
5
A Consensus Statement on acromegaly therapeutic outcomes.
Nat Rev Endocrinol. 2018 Sep;14(9):552-561. doi: 10.1038/s41574-018-0058-5.
6
MANAGEMENT OF ENDOCRINE DISEASE: Personalized medicine in the treatment of acromegaly.
Eur J Endocrinol. 2018 Mar;178(3):R89-R100. doi: 10.1530/EJE-17-1006. Epub 2018 Jan 16.
7
Somatostatin receptor ligands in the treatment of acromegaly.
Pituitary. 2017 Feb;20(1):100-108. doi: 10.1007/s11102-017-0791-0.
8
Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis.
J Clin Endocrinol Metab. 2014 May;99(5):1825-33. doi: 10.1210/jc.2013-3757. Epub 2014 Feb 25.
9
β-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly.
Endocrinology. 2013 Dec;154(12):4715-25. doi: 10.1210/en.2013-1672. Epub 2013 Oct 29.
10
Management of medically refractory prolactinoma.
J Neurooncol. 2014 May;117(3):421-8. doi: 10.1007/s11060-013-1270-8. Epub 2013 Oct 22.
Zotero 插件